{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-110945","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.327262+00:00","generated_at":"2026-06-09T13:24:25.866553+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BrainStorm cuts 30% headcount, CMO departs, plans NurOwn Phase 3b trial","bullets":["Reduction in force of ~30% with estimated severance costs of $450k-$900k, substantially complete by end of 2023.","Dr. Kirk Taylor steps down as EVP and Chief Medical Officer effective October 18, 2023, not due to any disagreement.","Company plans double-blind, placebo-controlled Phase 3b U.S. trial for NurOwn in ALS with open-label extension.","Total resource consumption to be reduced by ~50% to fund ALS development; exploring capital raising options.","Positions critical to Phase 3b trial and regulatory submission retained; clean room operations streamlined."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-110945","json":"https://secwatch.observer/filing/0001104659-23-110945.json","markdown":"https://secwatch.observer/filing/0001104659-23-110945.md","text":"https://secwatch.observer/filing/0001104659-23-110945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/tm2328929d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T13:24:25.866553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"251882c454","claim":"Dr. Kirk Taylor departed as EVP and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..","evidence_excerpt":"Dr. Kirk Taylor, EVP and Chief Medical Officer, stepped down from his post, effective as of October 18, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"EVP and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"a44c2dec94dccc78543b42a102475afdee42f74c","claim":"BRAINSTORM CELL THERAPEUTICS INC. announced a restructuring with charges of approximately $450,000-$900,000 (approximately 30%).","evidence_excerpt":"In connection with the RIF, the Company currently estimates it will incur a range of costs and expenses of approximately $450,000-$900,000, consisting primarily of cash severance costs and one-time termination benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $450,000-$900,000"},{"label":"Headcount","value":"approximately 30%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}